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Abstract
Unlike red blood cells (RBC) which are stored at 4°C, platelets are stored at 
22–24°C (room temperature) due to biophysical and biochemical changes induced 
by cold temperatures aggregately known as the ‘cold storage lesion’ (CSL). However, 
22°C storage greatly increases the risk of microbial growth, thus limiting the safe 
storage of platelets to only 5–7 days (versus 42 days for RBC). Consequent to the 
short shelf life of platelets, blood services face chronic shortages of these life-saving 
cells. To overcome both the risk of microbial contamination and the constrained 
supplies of platelets, renewed research into attenuating the CSL and/or determin-
ing where cold stored platelets are clinically suitable are ongoing. In this chapter, 
we show that the covalent grafting of methoxypolyethylene glycol (mPEG), a 
biocompatible polymer, to the membrane of platelets attenuates the CSL. Moreover, 
the grafted mPEG serves as a potent cryoprotectant allowing platelets to be stored 
at 4°C, or frozen at −20°C, while retaining normal platelet counts and biologic 
function. The successful development of platelet PEGylation may provide a means 
by which the cold storage of platelets can be achieved with a minimal loss of platelet 
quality while improving both platelet microbial safety and inventory.
Keywords: cryopreservation, cryoprotection, platelets, blood banking, cold 
storage, PEGylation, immunocamouflage, methoxypoly(ethylene glycol), polymer, 
aggregation
1. Introduction
Platelet adhesion and aggregation at the site of vascular injury are key events 
required for normal vascular homeostasis and wound repair. [1–4] Platelets are 
produced from megakaryocytes in the bone marrow and, while lacking a nucleus, 
contain a number of specialized granules such as alpha-granules and dense gran-
ules. Normal, resting platelets have a discoid morphology which changes upon 
activation to ‘spiny spheres’ arising from the formation of pseudopodia. This shape 
change coincides with the rearrangement of the actin cytoskeleton. Upon activa-
tion, platelets adhere to the subendothelium at sites of vascular injury, aggregate 
and initiate coagulation to stop bleeding (i.e. haemostasis).
Consequent to this essential role, platelet transfusions have evolved as a 
crucial therapeutic tool in the treatment of a large number of diverse clinical 
conditions including acute bleeding, surgery, treatment of a variety of cancers, 
patients with platelet abnormalities and autoimmune diseases such as Idiopathic 
Thrombocytopenic Purpura (ITP) [5]. To meet the increasing clinical needs, blood 
systems within developed countries produce in excess of 5,000,000 transfusion 
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Figure 1. 
Schematic view of the prevention of the platelet ‘cold storage lesion’ (CSL) by membrane PEGylation. Panel A: 
The normal discoid shape of platelets is lost as platelets are cooled below ~18°C. As a consequence of cooling, 
pseudopodia formation occurs leading to microaggregation of platelets (photo insert). Additionally, membrane 
proteins such as GP1b-IX aggregate on the surface. These changes lead to both mechanical and immunological 
clearance from the circulation. Panel B: PEGylation of platelets reduces both the shape change (e.g. fewer 
pseudopodia) and prevents microaggregation of the cold stored platelets. Consequent to the attenuation of the 
CSL lesions by the grafted mPEG, platelets can be stored for extended periods (> 7 days) at 4 or −80°C thereby 
improving platelet inventory and supply management while reducing the platelet discard rates. As noted, cold 
storage also significantly reduces the risk of microbial growth thus, potentially, improving transfusion safety.
doses annually [6]. However, demand for platelets continues to increase annually 
while the rate of blood/platelet donations are actually declining leading to an inven-
tory that is chronically constrained [7].
The constraint of platelet inventory is in large part due to an inability to safely 
store platelet products for greater than 5–7 days. Historically, platelets, like red 
blood cells (RBC), were stored at 4°C and successfully used clinically. However, 
multiple studies from the late 1960s to the early 1970s demonstrated that 4°C (i.e. 
cold) storage of platelets resulted in significantly reduced in vivo survival times 
compared to platelets stored at 22°C (warm storage) or endogenously produced 
platelets (2–4 vs. 7–9 vs. 10–12 days, respectively) [8–17]. The observed loss of in 
vivo viability and in vitro morphology and function was termed the platelet cold 
storage lesion (CSL) and resulted in the change in standard blood banking practice 
to storing platelets at 22–24°C by the early 1970s.
The CSL is multi-dimensional and is best characterized as the sum of all the 
deleterious changes in platelet morphology, biochemistry and function that 
arise from the time the blood is withdrawn to the time the cold-stored platelets 
are transfused. The CSL is characterized, in part, by loss of discoid shape (i.e. 
abnormal morphological forms), decreased mean platelet volume, increased size 
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heterogeneity, pseudopodia formation, increased release of platelet α-granules 
and cytosolic proteins, altered surface protein expression (e.g., glycoproteins 
such as GP1b-IX), increased procoagulant activity, aggregate formation, and 
reduced platelet counts—all of which are also characteristic of platelet activation 
(Figure 1A) [8–16, 18, 19]. In contrast, warm storage of platelets maintained 
platelet morphology, activation potential and greatly improved in vivo circula-
tion times [8–16].
However, the warm storage of platelets was not without risk as it was dem-
onstrated that warm storage significantly increased the risk for bacterial growth 
should bacteria be introduced to the platelet unit during collection [20–24]. Indeed, 
numerous North American screening studies have indicated that approximately 
1/3500 platelet units (primarily platelet rich plasma; PRP) are bacterially contami-
nated posing a potential hazard to already at-risk patients [23, 25, 26]. Consequent 
to this risk, multiple blood systems have implemented costly universal bacteriologic 
screening of donor platelets. Hence, development of new technologies to improve 
both platelet safety and inventories will be crucial in meeting the ever increasing 
demand for platelet products.
2. What was ‘OLD’ is ‘NEW’ again
Consequent to the clinical demand and supply chain issues, several studies over 
the last several years have re-explored the potential use of ‘cold-stored’ platelets. 
Initial excitement regarding cold-stored platelets arose in 2003, Hoffmeister et al. 
investigated the mechanism(s) underlying the CSL and experimentally demon-
strated that the shape change alone induced by cold storage itself did not result 
in poor platelet survival in a murine model [18, 19]. Instead, Hoffmeister et al. 
hypothesized that poor platelet survival resulted from an irreversible membrane 
clustering of alpha subunits of glycoprotein Ib (GPIbα). Their studies reported that 
exposed, terminal, beta-linked N-acetylglucosamine (βGlcNAc) residues on clus-
tered GPIbα were recognized by the lectin domain of type 3 complement receptors 
(CR3; αMβ2; CD11b/CD18) on liver and splenic macrophages. This immunorecogni-
tion resulted in the rapid clearance of cold stored donor platelets via phagocytosis. 
Hoffmeister also demonstrate that phagocytosis of briefly chilled murine platelets 
could be inhibited and in vivo survival prolonged by enzymatically galactosylating 
the terminal βGlcNAc residues on GPIbα. These findings led them to propose that 
enzymatically masking the exposed ßGlcNAc residues on the N-glycans of the clus-
tered GPIbα molecules by galactosylation would allow for the cold storage of human 
platelets without adversely affecting platelet function. However, enthusiasm for 
glycosylated platelets subsided when subsequent studies by Wandall et al. demon-
strated that galactosylation alone did NOT protect murine or human platelets from 
prolonged cold storage (e.g. >48 hours) [27].
More recently, the ‘old’ (1960) has become ‘new’ (2019) as transfusion scientists 
have begun to reexamine the clinical utility of platelets stored at 4°C. Indeed, the 
original 1960’s/70’s studies that initially discovered the platelet CSL, also reported 
that ‘cold-stored’ platelets were still effective in vivo in preventing acute blood loss. 
Hence, current clinical studies are investigating the use of 4°C stored platelets for 
at least some transfusion demands [28–45]. In general, recent studies suggest that, 
while these ‘old technology’ cold-stored platelets could be of benefit for acute hae-
mostatic transfusion needs, cold stored platelets still exhibit morphological changes 
and poor in vivo survival making them unlikely candidates for chronic replacement 
therapy in patients with already accelerated platelet clearance or as therapeutics for 
patients with cancer or who have undergone bone marrow transplantation.
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3. Hypothesis: attenuating the CSL via membrane-grafted mPEG
Consequent to our earlier work on polymer grafting to intact cells (e.g. RBC, 
lymphocytes), we hypothesized that the polymer induced immunocamouflage of 
platelet membranes with methoxypoly(ethylene glycol) [mPEG] could prevent 
or circumvent the immune recognition of cold stored platelets [46–49]. This 
hypothesis was supported by our previous studies on RBC and leukocytes (White 
blood cells; WBC) that demonstrated that the grafted polymer prevented cell:cell 
interactions (e.g. RBC Rouleaux formation; Phagocytosis of opsonized RBC; and 
Lymphocyte:APC) and membrane protein clustering (RBC CR1 aggregation) of the 
mPEG-modified cells while maintaining normal cellular function [50–71]. Hence, it 
was hypothesized that mPEG-grafting to platelets would prevent platelet aggrega-
tion and the clustering of GPIbα, and phagocytic recognition of the transfused 
mPEG-platelets (Figure 1B). Moreover, because soluble mPEG is a known cryo-
protectant, we hypothesized that the grafted polymer might also attenuate other 
‘cold-induced’ mechanical lesions of the CSL induced by cold temperatures and 
even freezing of donor platelets [72–79]. Indeed, the ability to freeze and recover 
donor platelets would both greatly increase platelet inventory and potentially 
expand the use of platelet therapy to geographic locations where platelet therapy is 
not commonly practiced.
4. Polymer engineering of platelets
All human experiments were done in accordance with the approval of the 
University of British Columbia Clinical Research Ethics Board and the Canadian 
Blood Services Ethics Review Board in accordance with the Code of Ethics of the 
World Medical Association (Declaration of Helsinki). Following informed con-
sent, fresh platelet rich plasma (PRP) and, in some cases, buffy coat platelets (the 
standard of care in Canada and Western Europe) were obtained from volunteer 
donors or the Canadian Blood Services Network Centre for Applied Development 
(NetCAD) Laboratory (Vancouver, BC). PRP samples are similar to the platelet 
preparations used clinically and have an advantage of a lower level of manipulation 
(e.g. centrifugation) than buffy coat or apheresis platelets. Care was taken to assure 
adequate representation of males and females and no individuals were excluded on 
the basis of age (within acceptable age range of donation of 17–71) or race.
Based on our previous studies, platelets were PEGylated using a semi-automated 
PEGylation device to maintain a constant platelet:polymer ratio (Figure 2) in a 
micromixing chamber to assure uniform polymer grafting [50, 52, 56, 71]. Platelets 
were modified with monofunctional (i.e. one binding site per chain) mPEG-succin-
imidyl propionate (SPA-mPEG). Previous studies (not shown) within our laborato-
ries determined that the optimal molecular weights for the PEGylation of platelets 
were 2–5 kDa which were used in these studies. For comparison of the effects of 
different linker chemistry, some studies simultaneously examined mPEG-benzotri-
azolyl carbonate (BTC-mPEG). Both SPA- and BTC-mPEG (Laysan Bio, Inc., Arab, 
AL, USA) react with protein lysine residues and covalently attach via formation 
of a stable amide bond (Figure 2C). To demonstrate the efficacy of the polymer-
mediated grafting, the mPEG-mediated immunocamouflage of platelet CD9 was 
assessed by flow cytometry. CD9 is a constitutive tetraspan membrane glycoprotein 
present on resting platelets that modulates cell adhesion and migration.
Control and PEGylated mini-units (approximately 50 ml/unit; ~500 × 109/L) 
of platelets were stored at 4 or 22°C with agitation per Canadian Blood Services 
standard operating procedures. Storage at −80°C was done separately in the sample 
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mini-unit blood banking bags. Storage was done for up to 12 days under the pre-
scribed conditions (note: normal storage at 22°C is only allowed for 7 days). Storage 
bags were sampled aseptically in biosafety cabinets; washing and lysis procedures 
were performed as described previously [80–82]. Platelet counts were determined 
using an Advia 120 Hematology Analyzer (Bayer Inc., Toronto, Canada).
5. Effect of 4°C storage on mPEG-platelets
The covalent grafting of mPEG to PRP platelets resulted in the efficient immu-
nocamouflage of CD9 (Figure 3A). As demonstrated in Figure 3A, virtually 100% 
of control platelets were CD9+, while the mPEG grafting to the platelets exhibited 
dose effect on the immunocamouflage of CD9. More importantly, the grafted 
polymer significantly decreased the aggregation of human platelets at 4°C. As 
microscopically demonstrated in Figure 3B, temperature exerted a significant 
effect on the morphology and microaggregation of control PRP preparations. 
As anticipated, minimal differences were observed in the control platelets at 
37° (i.e. in vivo conditions) versus 22°C (normal in vitro storage temperature). 
Importantly, PEGylation with either SCmPEG5000 or BTCmPEG5000 yielded 
platelets with comparable morphology to the control cells at 37 and 22°C. However, 
upon thermal transition from 22 to 4°C, control platelets were observed to form 
significant microaggregates characteristic of the CSL. In stark contrast, neither the 
SCmPEG5000 nor BTCmPEG5000 modified platelets exhibited any significant 
microaggregation consequent to the mPEG-mediated inhibition of cell:cell interac-
tion [66, 68]. Morphological analysis of the SCmPEG5000 and BTCmPEG5000 
modified platelets suggested that SCmPEG5000 better prevented cold induced 
shape change relative to the BTC polymer resulting in the SC-linker chemistry 
being further explored.
The mPEG-mediated inhibition of cold-induced platelet aggregation was also 
not a short term effect. As demonstrated in Figure 4, unmodified control platelets 
demonstrated significant shape change, microaggregation, and a dramatic (~30%) 
decrease in platelet count. In contrast, minimal microaggregation was noted in the 
PEGylated samples following 12 days storage at 4°C. PEGylated platelets also retained 
a more discoid shape (though some pseudopod formation was noted). Due to the 
inhibition of microaggregation and inhibition of activation induced shape change, the 
mPEG-grafted platelets also resulted in a significantly improved platelet count.
Figure 2. 
Production of mPEG-platelets and the SVAmPEG reaction scheme and grafting efficacy. Panel A: semi-
automated PEGylation device allowing for control of the mPEG:platelet ratio for uniform grafting levels 
[71]. Panels B and C: the structure (B) and reaction scheme (C) for activated SVA-mPEG. The SVA-linker 
chemistry forms a stable amide bond with platelet membrane proteins. Panel D: Fluorescein-conjugated SVA-
mPEG demonstrated that platelets were uniformly modified using our semi-automated methodology.
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Importantly, PEGylated platelets were functionally normal as evidenced by their 
in vitro aggregation response to thrombin. As shown in Figure 5A, phase contrast 
microscopy of washed control and PEGylated platelets resuspended in normal 
plasma both maintained a smooth, resting morphology. However, in response to 
2 IU/mL thrombin activation (Figure 5B), both control (a) and PEGylated (b; 
10 mM SCmPEG-5000) platelets fully aggregated at 37°C (1000 rpm stir speed) 
in an aggregometer (Chronolog, Havertown, PA, USA). This normal aggregation 
of PEGylated platelets occurred despite the significant immunocamouflage (see 
below) of the platelet membrane surface. Moreover, as shown in Figure 5C, phase 
contrast microscopy demonstrated that control and PEGylated platelets form 
microscopically very similar thrombin-induced clots. Interestingly, if PEGylated 
platelets were suspended in PEGylated plasma essentially no in vitro aggrega-
tion was observed, likely due to the PEGylation of plasma proteins involved in 
Figure 4. 
PEGylation inhibited 4°C cold-induced platelets aggregation and shape change. The improved viability of the 
cells is accompanied by maintenance of the pre-storage platelet count (day 0).
Figure 3. 
Immunocamouflage of platelets by grafted mPEG. Panel A: CD9 is effectively camouflaged by grafted 
5 kDa polymers of SC- and BTC-activated mPEG. The efficacy of immunocamouflage was a function of 
mPEG grafting concentration. Panel B: While both SC- and BTC-mPEG demonstrated similar efficiency 
in camouflaging CD9, photomicrographs showed that the SCmPEG better preserved platelet morphology at 
4°C. SCmPEG was consequently used for all further studies.
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clot formation. However, these data indicated that PEGylated platelets would be 
functional when transfused into an actively bleeding patient regardless of whether 
they were stored in the presence of PEGylated plasma, normal plasma or a platelet 
storage solution as their functionality was restored in the presence of normal 
plasma. Thromboelastographic (Haemonetics, Braintree, MA) analysis of control 
and PEGylated platelets further demonstrated the normality of polymer modified 
platelets in response to multiple platelet agonists. As noted in Figure 5D, control 
and PEGylated platelets demonstrated virtually identical results when exposed 
to adenosine diphosphate (ADP), arachidonic acid (AA) or thrombin activation 
indicating that clot formation should not be adversely affected by PEGylation—
especially since in most circumstances PEGylated donor platelets will represent 
~50% or, most typically, much less of the platelets in a clot.
Clinically, visual inspection for ‘swirl’ may be the only pre-transfusion ‘qual-
ity’ test of the platelet unit—though even this is rarely done. The swirl test is a 
Figure 5. 
PEGylated platelets are functional and aggregate in vitro in response to agonists. Panel A: Phase contrast 
microscopy of control and PEGylated PRP platelets in plasma demonstrate that both populations maintain 
a smooth, resting morphology. Panel B: Aggregometer analysis of control (c) and PEGylated (p) platelets 
demonstrate normal responses to 2 IU/mL thrombin (37°C; 1000 rpm). Panel C: Control and PEGylated PRP 
platelets form microscopically very similar thrombin-induced clots. Panel D: PEGylation did not affect platelet 
thromboelastography (TEG) as denoted by the virtually identical TEG tracings. These results demonstrated 
that PEGylated platelets participated normally in the in vitro clotting assay. Platelet mapping with TEG 
determines total platelet function. The two symmetric arms show the same results. Shown are representative 
responses of control (c; black lines) and PEGylated (red lines; SCmPEG5000) platelets at rest (baseline) and in 
response to ADP, AA, and thrombin activation.
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Figure 6. 
ThromboLUX dynamic light scattering analysis of platelets following 6 days storage. Panel A: Control platelets 
stored at 22°C. panel B: Control platelets stored at 4°C. panel C: ScmPEG5000 (10 mM) platelets stored at 
4°C. As shown, mPEG grafting resulted in significant cryoprotection. The Y-axis is particle count while the 
x-axis reflects the hydrodynamic radius distribution. All samples were prepared from the same donor platelet 
unit.
noninvasive method that literally works by swirling the bag and looking for light 
diffraction (i.e. refractiveness) [83–86]. Due to the discoid shape of resting (unac-
tivated) platelets, light is diffracted creating a cloud- or swirl-like appearance of 
the bag. Platelet activation causes a disc to sphere morphology change where upon 
orientation dependent changes in light diffraction are no longer observed. A dull 
platelet bag is deemed ‘activated’ while a refractive bag is ‘resting’. Unsurprisingly, 
despite the low cost (i.e. free) of the swirl test, it actually tells very little as to the 
quality of the platelet unit. Over the last few years, a new technology has been 
developed to quantitatively measure platelet quality using dynamic light scattering. 
The ThromboLUX (LightIntegra Technology, Vancouver, BC) quantitatively mea-
sures platelet morphology (shape change) and temperature response and provides a 
quantitative replacement to the qualitative and subjective ‘platelet swirl’ [62, 83–85, 
87–92]. Mechanistically the ThromboLUX utilizes dynamic light scattering to exam-
ine a small volume (~30 μl) of platelets to quantitatively assess platelet size and 
morphological changes arising from temperature cycling (37 to 20 to 37°C). The 
ThomboLUX generates a Dynamic Light Scattering (DLS) value that correlates with 
platelet activation status. Moreover, the ThromboLUX is capable of quantitating 
the number of platelet-derived microparticles and evidence of microbial contami-
nation. The ThromboLUX technology has been clinically validated and provides 
a correlation between the DLS score and a patients corrected count increment at 
24 hours (CCI24) post transfusion [84]. Shown in Figure 6A is the ThromboLUX 
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profile of control platelets stored 6 days at 22°C. However, cold storage of the same 
platelet preparation resulted in a dramatic shift of the platelet peak (Figure 6B) 
with the appearance of microparticles, smaller platelets and platelet aggregates. In 
contrast, cold stored (6 days) PEGylated platelets (10 mM, 5 kDa) yielded a DLS 
profile similar to the 22°C stored platelets with no evidence of aggregate formation 
and minimal microparticle formation (Figure 6C).
6. Effect of −80°C storage on mPEG-platelets
To further assess the cryoprotective effects of the grafted mPEG polymer, freez-
ing studies were conducted on the control and SCmPEG platelets. While previous 
work on PEG as a cryoprotectant utilized a soluble form, work with PEG and other 
cryoprotectants (DMSO and Trehalose) demonstrated that the primary site of 
protection was at the level of the cell membrane [72–79]. As shown in Figure 7, 
following 12 days storage at −80°C, covalently bound SCmPEG provided significant 
cryoprotection as reflected by both platelet morphology and improved cell counts. 
This finding is in stark contrast to control platelets which exhibited significant 
fragmentation and dramatically reduced cell counts post storage and thawing.
The covalent grafted mPEG exerted additional benefits post thaw. As shown 
in Figure 8, SCmPEG-grafted platelets exhibited improved morphology, and 
less fragmentation, immediately post-thaw when compared to control cells. 
Indeed, the grafted polymer provided comparable (or better) cryoprotection than 
DMSO. Moreover, following washing and re-concentration of the freeze-thaw 
Figure 7. 
PEGylation inhibited −80°C cold-induced platelets aggregation and shape change. The improved viability of 
the cells is accompanied by significantly improved maintenance of the pre-storage platelet count (day 0).
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Figure 9. 
Post storage at −80°C, the aggregation of control and SCmPEG platelets was assessed in response to thrombin 
(2 IU/mL). As shown, thawed control platelets exhibited limited aggregation (~40% light transmittance) after 
8 minutes. In contrast, the PEGylated platelets demonstrated robust aggregation (100% light transmittance 
at ~4 minutes). Shown are representative responses of control (black lines) and PEGylated (red lines; 
SCmPEG5000) platelets.
Figure 8. 
PEGylation gives rise to significant cryoprotection from freeze-thaw injury. As shown, after 12 days of storage 
at −80°C, unmodified control platelets exhibited significant platelet destruction, loss of morphology, and a 
significant (p < 0.001) decrease in platelet count. In contrast, subsequent to freeze-thaw, PEGylated platelets 
demonstrated normal discoid morphology and few detectable microaggregates and were very comparable to 
platelets cryopreserved with DMSO, the standard cryoprotectant for frozen RBC and platelets. Moreover, 
unlike control platelets, the PEGylated sample did not form microaggregates when incubated at 22°C.
11
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control and SCmPEG platelets, control platelets demonstrated significant aggrega-
tion when stored at 22°C overnight (12 hours). In contrast, the SCmPEG-platelets 
demonstrated no aggregation over the same 12 hour time frame.
While the maintenance of morphology and platelet numbers post −80 storage 
was promising, the key question was whether these platelets were functional. To 
assess platelet function, thrombin (2 IU/ml) induced aggregation was assessed. As 
shown in Figure 9, thawed control platelets exhibited a poor response to thrombin 
(see Figure 5B for a normal response) as demonstrated by very limited aggrega-
tion. Moreover, the aggregation of the control platelets was very slow as seen by 
the slope of the aggregation curve. In contrast, the thawed SCmPEG platelets 
demonstrated significant, and rapid, thrombin mediated aggregation. Indeed, near 
maximal aggregation was achieved within approximately 3 minutes and very closely 
resembled the thrombin activation curves of fresh control and SCmPEG PRP (see 
Figure 5B).
7. Discussion
Platelet transfusions are a critical component in the treatment of both trau-
matic acute injury and a number of chronic diseases. However, unlike RBC which 
are stored at 4°C, platelets are stored at 22–24°C (room temperature) due to the 
induction of the CSL at temperatures below ~18°C. While the CSL encompasses 
a multitude of biophysical and biochemical changes, perhaps the most apparent 
effect is the production of platelet aggregates. To prevent the CSL, blood services 
worldwide have successfully stored platelets at 22°C. However, warm storage has 
its own risks as it greatly increases the risk for microbial growth limiting the safe 
storage of platelets to only 5–7 days (versus 42 days for RBC) and the outdating of 
a significant number of donor units. Consequent to the short shelf life of platelets, 
blood services face chronic shortages of these life-saving cells. To overcome both the 
risk of microbial contamination and the constrained supplies of platelets, renewed 
research into attenuating the CSL and/or determining where cold stored platelets 
are clinically suitable are ongoing.
To circumvent the microbial risk, and improve platelet inventory, our research 
has examined the potential use of cold stored, mPEG-grafted, platelets. As dem-
onstrated by our in vitro experimental findings, the covalent grafting of mPEG to 
donor platelets significantly reduced the severity of the 4°C CSL while maintaining 
normal haemostatic function. This was evidenced by the maintenance of ‘normal’ 
platelet morphology, the lack of microaggregation, and normal platelet activation 
by thrombin and normal aggregation as determined by thromboelastography and 
aggregation studies. Moreover, due to the cryoprotective effects of the grafted 
mPEG, polymer-modified platelets could be stored at −80°C and thawed and still 
retained normal morphology and haemostatic function. In contrast, the freez-
ing of normal platelets in the absence of a cryoprotectant (e.g. DMSO) resulted in 
significant cellular damage resulting in vastly reduced recovery, loss of haemostatic 
function and subsequent microaggregation when incubated at room temperature 
for 12 hours.
Interestingly, while not a focus of this chapter, polymer size (e.g. 2, 5 or 20 kDa) 
was an important factor when considering the cryoprotection of platelets while 
maintaining the unique functions of the platelet. In contrast to RBC and WBC in 
which longer chain polymers (e.g. 20 kDa) were optimal, short chain polymers 
(e.g. 2–5 kDa) were optimal for platelet cryopreservation. However, the disparity 
between RBC and WBC relative to platelets is not as unanticipated as it appears. 
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The goal of RBC and WBC PEGylation is to induce immunocamouflage (i.e. prevent 
immune recognition) and, especially for WBC, prevent cell:cell communication 
(e.g. allorecognition). Clearly for platelets, cell:cell interaction is crucial for their 
haemostatic function. Hence, the primary goal of platelet PEGylation is to prevent 
thermal injury to the membrane while maintaining normal platelet function. While 
all sizes of the grafted polymer could prevent cryogenic injury, long chain polymers 
inhibited platelet activation and their subsequent aggregation. In contrast, the 
short 2–5 kDa polymers provided adequate cryoprotective effects while allowing for 
normal agonist-driven activation.
8. Conclusions
PEGylation of donor platelets with short chain (2–5 kDa) mPEG effectively 
prevent the overt morphological changes arising from the CSL. Moreover, the 
polymer-grafted platelets retained their normal haemostatic function following 
both cold storage (4°C) and freezing (−80°C) as evidenced by thromboelastogra-
phy and aggregation studies. Importantly, cold storage of platelets would improve 
transfusion safety as it would diminish the risk of microbial growth in a blood 
product destined for use in at risk patients. Also of potential clinical and economic 
importance was the finding that mPEG-grafted platelets withstood freezing in 
the absence of other cryoprotectants such as DMSO. The use of frozen platelets, 
requiring no DMSO removal step, could expand the availability of platelet transfu-
sions to geographic regions in which they are not currently available or where donor 
recruitment or production facilities do not exist. The successful implementation of 
this technology for the cold storage of platelets would be of significant benefit to 
transfusion recipients by increasing the availability of platelets for transfusion.
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